Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Puromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | NPEPPS | P55786 | 12/20 | 0.99 |
| ▸ | ANPEP | P15144 | 10/20 | 0.99 |
| ▸ | LMNA | P02545 | 1/20 | 0.99 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.99 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Puromycin SCHEMBL2483615 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL2348795 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL31237590 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL29713430 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL4317 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL5067276 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL9724067 | 0.99 | SMN1; SMN2 (0.99) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL24206459 | 0.99 | NPEPPS (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL21306559 | 0.99 | NPEPPS (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 | |
| Puromycin SCHEMBL22409382 | 0.99 | NPEPPS (1.00) | SMN1; SMN2TP53CYP3A4HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 839 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536236-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | University of Utah Research Foundation (US) | 2025-04-16 | — | — | EP | claimed |
| CN-117947097-A | Immortalized pancreatic duct adenocarcinoma related fibroblast line and construction and application thereof | 复旦大学附属肿瘤医院 | 2024-04-30 | — | — | CN | claimed |
| WO-2023239747-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-12-14 | — | — | WO | claimed |
| EP-4061393-A1 | METHOD FOR THE DEVELOPMENT OF A DELIVERY PLATFORM TO PRODUCE DELIVERABLE PTD-IVT-MRNA THERAPEUTICS | Aristotle University of Thessaloniki - Elke (GR) | 2022-09-28 | — | — | EP | claimed |
| CN-109097335-B | Method for inducing malignant transformation from normal liver stem cell to liver cancer stem cell | 刘卫辉 | 2022-08-19 | — | — | CN | claimed |
| WO-2021094792-A1 | METHOD FOR THE DEVELOPMENT OF A DELIVERY PLATFORM TO PRODUCE DELIVERABLE PTD-IVT-mRNA THERAPEUTICS | ARISTOTLE UNIVERSITY OF THESSALONIKI E.L.K.E. (GR) | 2021-05-20 | — | — | WO | claimed |
| CN-109097335-A | Abductive approach of the normal liver stem cells to liver-cancer stem cell vicious transformation | 刘卫辉 | 2018-12-28 | — | — | CN | claimed |
| US-20110271397-A1 | MOLECULAR CLOCK MECHANISM OF HYBRID VIGOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-11-03 | — | — | US | claimed |
| WO-2011029053-A1 | HUMAN EMBRYONIC STEM CELLS FOR HIGH THROUGHOUT DRUG SCREENING | BUCK INSTITUTE FOR AGE RESEARCH (US) | 2011-03-10 | — | — | WO | claimed |
| WO-2010045218-A1 | MOLECULAR CLOCK MECHANISM OF HYBRID VIGOR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-04-22 | — | — | WO | claimed |
| WO-2003055489-A1 | 2,4-DIAMINO-PYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003055890-A1 | THIENOPYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003055866-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| CN-122080174-A | T cell receptor capable of binding to HPV 16E 6 antigen presented by HLA-C14:02 molecule and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIV OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026098510-A1 | CONSTRUCTION METHOD FOR QUADRUPLE-RESISTANT ANIMAL AND USE THEREOF | 广州明迅生物科技有限责任公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-0187547-A2 | Synthetic polymeric drugs | Ceskoslovenska akademie ved (CS) | 1986-07-16 | — | — | EP | disclosed |
| EP-0066956-B1 | ENKEPHALINASE ENZYME INHIBITING COMPOUNDS | PFIZER INC. (US) | 1984-08-08 | — | — | EP | disclosed |
| EP-0066956-A1 | Enkephalinase enzyme inhibiting compounds | PFIZER INC. (US) | 1982-12-15 | — | — | EP | disclosed |
| US-4329495-A | USEFUL AS ANALGESICS OR ANTICONVULSANTS, CHIRAL 2-(2-BENZYL-3-MERCAPTOPROPIONYLAMINO)-THIOBUTYRIC ACIDS, OR ALKANOL DERIVATIVES | PFIZER INC. (US) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | ATXN2, ATXN2L, ATP6V1B2 | SMN1; SMN2 49/4885TP53 1585/4885CYP3A4 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.